⌘K
t
ANGLE plc will release its interim results for the six months ended 30 June 2025 on Tuesday 9 September 2025. A virtual meeting for analysts will be held at 11:00 am BST on the same date, with a live webcast accessible via ANGLE's Investor Centre page and Q&A reserved for analysts. A recording of the webcast will be made available following the meeting.
| Date | 5 Sept 2025 |
| Time | 14:58:52 |
| Category | Results |
| ID | 2714Y |
|
|
05 September 2025 |
ANGLE plc ("the Company")
Notice of Interim Results and Webcast
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, will be releasing its interim results for the six months ended 30 June 2025 on Tuesday 9 September 2025.
A meeting for analysts will be held at 11:00 am BST on Tuesday 9 September 2025. In light of the planned tube strikes this will be held virtually.
A live webcast of the analyst meeting can be accessed via ANGLE's Investor Centre page, https://angleplc.com/investor-relations/corporate-presentations/, with Q&A participation reserved for analysts only. Please register in advance and log on to the webcast approximately 5 minutes before 11:00 am on the day of the results. A recording of the webcast will be made available on ANGLE's website following the results meeting.
For further information:
|
ANGLE plc |
+44 (0) 1483 343434 |
|
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
|
|
|
Berenberg (NOMAD and Corporate Broker) Toby Flaux, Ciaran Walsh, Milo Bonser |
+44 (0) 20 3207 7800 |
|
FTI Consulting Simon Conway, Sam Purewal Matthew Ventimiglia (US) |
+44 (0) 203 727 1000 +1 (212) 850 5624 |
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com